NCT06891300View on ClinicalTrials.gov

Understanding and Treating Suicidal Ideation With Ketamine

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 8, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Suicidal IdeationMajor Depressive Disorder (MDD)
Interventions
DRUG

ketamine hydrochloride

Participants will undergo intravenous (IV) ketamine infusions (0.5 mg/kg infused over 40 minutes) under medical supervision. Treatments will be administered twice weekly for two weeks, for a total of four infusions.

Trial Locations (1)

K1Z7K4

RECRUITING

Royal Ottawa Mental Health Centre, Ottawa

All Listed Sponsors
lead

The Royal's Institute of Mental Health Research

OTHER